Mela Sciences Inc (MELA) 1.12 $MELA Cipher

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Mela Sciences Inc (MELA) 1.12 $MELA

Cipher Pharmaceuticals Proposes Adding Rosemary A. Crane and Dr. Renee P. Tannenbaum To Board of Directors
CNW Group - Thu Apr 07, 6:00AM CDT
Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company" today announced that Rosemary A. (Rose) Crane and Dr. Renee P. Tannenbaum, two pharmaceutical industry leaders, are being proposed for election to Cipher's Board of Directors at the Company's Annual and Special Meeting on May 5, 2016.
CPH.TO: 6.58 (+0.03), MELA: 1.12 (+0.01), ZGNX: 9.21 (+0.08), CPHR: 4.96 (-0.04), ABBV: 66.94 (+0.71), TEVA: 53.61 (+0.11)

MELA Sciences Announces That Its Corporate Name Change to STRATA Skin Sciences Will Be Effective January 5, 2016
GlobeNewswire - Mon Jan 04, 12:00PM CST
MELA Sciences, Inc. (Nasdaq:MELA), today announced that its corporate name change to STRATA Skin Sciences, Inc. will be effective Tuesday, January 5, 2016 and that it will trade under the symbol "SSKN" on the Nasdaq Stock Market.
MELA: 1.12 (+0.01)

MELA Sciences Announces Corporate Name Change to STRATA Skin Sciences to Reflect Broader Dermatology Commitment
GlobeNewswire - Tue Dec 22, 7:00AM CST
MELA Sciences, Inc. (Nasdaq:MELA), today announced that it will be changing its corporate name to STRATA Skin Sciences, Inc. effective Tuesday, January 5, 2016 and that it will trade under the symbol "SSKN" on the Nasdaq Stock Market.
MELA: 1.12 (+0.01)

MELA Sciences Reports Supplemental Financial Information on XTRAC(R) Recurring Revenue
GlobeNewswire - Fri Nov 13, 1:21PM CST
MELA Sciences, Inc. (NASDAQ:MELA) reported today additional information related to its Third Quarter 2015 financial results press release dated November 12, 2015, clarifying the comparative revenue information from its XTRAC recurring revenues.
MELA: 1.12 (+0.01), PHMD: 0.26 (+0.02)

MELA Sciences promotes Christina L. Allgeier to CFO
M2 - Thu Nov 12, 3:58AM CST
Medical technology company MELA Sciences (NasdaqCM:MELA) reported on Wednesday that it has promoted Christina L. Allgeier to the position of chief financial officer.
MELA: 1.12 (+0.01)

MELA Sciences Appoints Christina L. Allgeier Chief Financial Officer
GlobeNewswire - Wed Nov 11, 1:52PM CST
MELA Sciences, Inc. (NASDAQ:MELA), a medical technology company dedicated to developing and commercializing innovative products for the treatment and diagnosis of serious dermatological disorders, today announced that Christina L. Allgeier has been promoted to the post of Chief Financial Officer of MELA Sciences, Inc., effective November 9, 2015. Ms. Allgeier is a graduate of Penn State University and is a Certified Public Accountant with significant SEC experience. Ms. Allgeier joined MELA as a result of the recent acquisition of the XTRAC and VTRAC business.
MELA: 1.12 (+0.01)

MELA Sciences to Report Third Quarter Financial Results on Thursday, November 12
GlobeNewswire - Thu Oct 29, 7:00AM CDT
MELA Sciences, Inc. (NASDAQ:MELA), a medical technology company dedicated to developing and commercializing innovative products for the diagnosis and treatment of serious dermatological disorders, will release third quarter financial results on Thursday, November 12, after the market close. MELA Sciences President and Chief Executive Officer, Michael Stewart, and Robert Cook, Chief Financial Officer, will host a conference call at 4:30pm Eastern Time to review the Company's progress and answer questions.
MELA: 1.12 (+0.01)

Intuitive Surgical Outshines Q3 Earnings Estimates, Stock Up
Zacks Equity Research - Zacks Investment Research - Wed Oct 21, 9:20AM CDT
Intuitive Surgical (ISRG) shares soar following company's impressive third quarter 2015 results.
ISRG: 693.87 (-1.89), MASI: 52.93 (-0.04), MELA: 1.12 (+0.01), MZOR: 22.56 (-0.10)

Remedy Pharmaceuticals Announces Appointment of Chief Financial Officer
BusinessWire - Wed Oct 14, 8:30AM CDT
Remedy Pharmaceuticals, a clinical stage pharmaceutical company focused on the development and commercialization of a revolutionary, breakthrough drug, CIRARA(TM), for treating acute central nervous system conditions -- where there are inadequate or no approved existing therapies -- announced today the appointment of Richard I. Steinhart as Chief Financial Officer effective immediately.
MELA: 1.12 (+0.01)

MELA Sciences Announces Election of R. Rox Anderson, M.D., to Board of Directors
GlobeNewswire - Tue Oct 13, 7:30AM CDT
MELA Sciences, Inc. (NASDAQ:MELA), a medical technology company dedicated to developing and commercializing innovative products for the diagnosis and treatment of serious dermatological disorders, announced today that R. Rox Anderson, M.D., was elected to the Company's board of directors at its Annual General Meeting of Stockholders held on September 30, 2015 in Philadelphia, PA. With Dr. Anderson's election, the MELA board of directors has increased to seven members, six of whom are independent.
MELA: 1.12 (+0.01)

Dermatology Diagnostic Devices Market - Technavio Unveils Global Trends & Forecast
BusinessWire - Thu Sep 24, 9:35AM CDT
Technavio has published a new report on the global dermatology diagnostic devices market, which is expected to grow at a CAGR of more than 9% from 2015-2019.
MELA: 1.12 (+0.01)

Is MELA Sciences an Incredible Momentum Stock? 3 Reasons Why MELA Will Be Tough to Beat
Zacks Equity Research - Zacks Investment Research - Tue Sep 22, 7:39AM CDT
MELA Sciences (MELA) is an impressive stock as it has a strong Momentum Score, favorable Zacks Rank and is also seeing positive estimate revisions
MELA: 1.12 (+0.01)

MELA Sciences Reports Second Quarter 2015 Financial Results
GlobeNewswire - Thu Aug 13, 3:01PM CDT
MELA Sciences, Inc. (NASDAQ:MELA), a medical technology company dedicated to developing and commercializing innovative products for the diagnosis and treatment of serious dermatological disorders, today reported financial results for the second quarter ended June 30, 2015.
MELA: 1.12 (+0.01)

MELA Sciences to Report Second Quarter Financial Results on Thursday, August 13
GlobeNewswire - Wed Aug 12, 7:01AM CDT
MELA Sciences, Inc. (NASDAQ:MELA), a medical technology company dedicated to developing and commercializing innovative products for the diagnosis and treatment of serious dermatological disorders, will release second quarter financial results on Thursday, August 13, after the market close. MELA Sciences President and Chief Executive Officer, Michael Stewart, and Robert W. Cook, Chief Financial Officer, will host a conference call at 4:30pm Eastern Time to review the Company's progress and answer questions.
MELA: 1.12 (+0.01)

Hot Stock: MELA Sciences, Shares Drop 6.9% (MELA)
Comtex SmarTrend(R) - Fri Jun 26, 10:18AM CDT
MELA Sciences (NASDAQ:MELA) is one of today's worst performing low-priced stocks, down 6.9% to $1.22 on 1.1x average daily volume. MELA Sciences has traded 223,000 shares thus far today, vs. average volume of 207,000 shares per day. The stock has underperformed the Dow (-6.9% to the Dow's 0.4%) and underperformed the S&P 500 (-6.9% to the S&P's 0.1%) during today's trading.
MELA: 1.12 (+0.01)

North American Dermatology Treatment Devices Market 2015-2019 - Types (Liposuction, Microdermabrasion, Lasers) & Application (Cancer Diagnosis, Psoriasis, Hair Removal) Analysis
M2 - Tue May 26, 5:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/g3tbwq/north_american) has announced the addition of the "North American Dermatology Treatment Devices Market by Types (Liposuction, Microdermabrasion, Lasers) & by Application (Cancer Diagnosis, Psoriasis, Hair Removal) - Forecast to 2019" report to their offering. The North American dermatology treatment devices market is estimated to grow at a CAGR of 10.1% from 2014 to 2019 The U.S holds the largest share of the dermatology treatment devices market; however, the Canadian market is expected to grow at the highest CAGR of 11.5% during the forecast period. Factors such as rising skin disorders, growing demand for diagnosis from the geriatric population, increasing demand for dermatologists, and technology advantages are driving market growth. However, factors such as lack of awareness, competitive pricing of devices, and lack of dermatology care are hindering the growth of this market. In this report, the North American dermatology treatment devices market has been broadly classified on the basis of types. This includes LED light therapy devices, lasers, electrosurgical equipment, liposuction devices, microdermabrasion, and cryotherapy. The lasers segment held the largest share in the treatment devices market, growing at a CAGR of 12.3% during the forecast period. Geographically, the U.S commanded the largest share of 86.0% of the North American dermatology treatment devices market in 2014, followed by Canada. The dermatology treatment devices market in the U.S. is primarily driven by increasing demand from the geriatric population and rise in insurance coverage among citizens due to increasing employment. Canada is the fastest-growing market in the North American region, growing at a CAGR of 11.5% during the forecast period. The North American dermatology treatment devices market is a competitive market with a number of market players. As of 2014, the North American dermatology treatment devices market is estimated to be dominated by Photomedex, Inc., Verisante technology, Inc., MELA Sciences, Inc., Michelson diagnostics Ltd, Leica Microsystems, Fotofinder systems GMBH, FEI Company, Solta medical, Syneron medical Ltd., Lumenis Ltd., Cutera, Inc., Cynosure, Inc., AMD global telemedicine Inc, Ambicare Health Ltd, and ALMA Lasers, Ltd. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Market Overview 5 North American Dermatology Treatment Devices Market, By Product 6 North American Dermatology Treatment Devices Market, By End User 7 North American Dermatology Treatment Devices Market, By Country 8 Dermatology Treatment Devices Market: Competitive Landscape 9 Dermatology Treatment Devices Market, By Company - ALMA Lasers, Ltd. - AMD Global Telemedicine Inc. - Ambicare Health Ltd - Cutera, Inc. - Cynosure, Inc. - FEI Company - Fotofinder Systems GMBH - LEICA Microsystems - Lumenis Ltd. - MELA Sciences, Inc. - Michelson Diagnostics Ltd. - Photomedex, Inc. - SOLTA Medical - Syneron Medical Ltd. - Verisante Technology, Inc. For more information visit http://www.researchandmarkets.com/research/g3...h_american
ELOS: 7.30 (-0.07), CYNO: 53.51 (-1.45), MELA: 1.12 (+0.01), LMNS: 13.76 (+0.04), FEIC: 106.45 (+0.03)

Traders Get Bullish on Shares of MELA Sciences, Shares Up 6.8% (MELA)
Comtex SmarTrend(R) - Thu May 21, 10:15AM CDT
MELA Sciences (NASDAQ:MELA) is one of today's best performing low-priced stocks, up 6.8% to $1.73 on 1.9x average daily volume. MELA Sciences has traded 385,000 shares thus far today, vs. average volume of 205,000 shares per day. The stock has outperformed the Dow (6.8% to the Dow's 0.0%) and outperformed the S&P 500 (6.8% to the S&P's 0.2%) during today's trading.
MELA: 1.12 (+0.01)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Disney Springs Hotel Rates Test Holiday Demand Depth

Updated Category News Views 161

A $145 room rate is the sort of holiday bait that gets my attention before the fake snow does. Disney Springs Resort Area Hotels are extending a seasonal offer for stays through Dec. 18, 2026, with bookings open only through Nov. 20. That is a very narrow selling window, and it tells you plenty: these seven independent hotels want to fill rooms during a lucrative but...

Continue Reading
Decibel's Export Engine Masks a Domestic Sales Slip

Updated Category News Views 24

Decibel’s overseas business is doing the heavy lifting, and it is not doing it quietly. Third-quarter net revenue reached $35.1 million, up 7% from a year earlier, while international sales jumped 44% to a record $12.1 million. That split matters more than the headline. Canadian adult-use sales fell 6% to $23.0 million, which means the company is proving it can find...

Continue Reading
Dario's WebMD Deal Opens a Vast, Unproven Channel Path

Updated Category News Views 12

One partnership can look like a gold mine from across the valley; getting the ore out is another matter entirely. DarioHealth has struck a strategic partnership with WebMD Health Services that could put its multi-condition care platform in front of an enormous commercial ecosystem: more than 3,500 employers and 65 million covered lives. That is a meaningful distribution...

Continue Reading
BetterInvesting Puts ELMD and FIVE Under a Fresh Lens

Updated Category News Views 90

Two familiar market traps are hiding in this otherwise useful announcement: mistaking a study candidate for a buy signal, and treating the word undervalued like it fell from a mountaintop. BetterInvesting has named Electromed Inc. as its “Stock to Study” and Five Below Inc. as its “Undervalued Stock” for the January-February 2027 issue of its magazine. That is...

Continue Reading
Tactical Tomahawk Motor Deal Puts Propulsion in Focus

Updated Category News Views 299

A missile program lives or dies on unglamorous hardware, and solid rocket motors are about as unglamorous as it gets until somebody cannot build enough of them. Raytheon has awarded Ursa Major and Avio USA a joint contract to develop solid rocket motors for the U.S. Navy’s Tactical Tomahawk missile program. That is the whole headline, and it matters more than the thin...

Continue Reading
Color Me Mine Tests Florida's Creative Leisure Demand

Updated Category News Views 72

Pottery studios are not exactly the sort of thing that makes markets pound the table, but Florida’s latest Color Me Mine push deserves a closer look. The company signed three franchise agreements in 2026 for Panama City Beach, Doral and Boca Raton, adding planned growth to a state where it already operates 11 studios. For a private franchisor, this is not a quarterly...

Continue Reading
Arbor Realty's Loan Mess Meets a Dividend Shutdown

Updated Category News Views 58

A dividend suspension lands differently when the loan book is already coughing up smoke. Arbor Realty Trust’s latest disclosed numbers are not the sort that investors can shrug off as one ugly quarter and forget by Friday. The company reported a third-quarter 2026 GAAP net loss of $85.4 million, suspended its quarterly cash dividend effective immediately, and described...

Continue Reading
Washington-to-Asia Advisory Deal Targets Policy Risk

Updated Category News Views 109

Policy bottlenecks are becoming a cost center across Southeast Asia. That is the plain-English backdrop for the strategic partnership announced November 18, 2026, by Beacon Global Strategies and Vriens & Partners. Neither firm is selling a factory, a chip design, or a new energy project. They are selling something companies increasingly cannot afford to improvise: a...

Continue Reading
WeWalk Brings Diabetes Support Back to Dubai Science Park

Updated Category News Views 56

Before sunrise on 21 November, a 3.5 km route in Dubai Science Park will carry a purpose bigger than sneakers and weekend fitness. WeWalk is returning for its seventh edition, with TECOM Group PJSC and Dubai Charity Association again putting the event behind support for children living with diabetes. That deserves to be said plainly: this is a community health effort, not...

Continue Reading
Vision Marine's Cash Cleanup Meets a Hard Reality Ahead

Updated Category News Views 51

A boat dealer slashing debt by $27.5 million deserves a nod, even when the rest of the ledger still makes your eyebrows climb. Vision Marine Technologies turned fiscal 2026 into a working-capital cleanup job: inventory came down hard, floor-plan financing nearly vanished, and operating cash flow finally turned positive. For NASDAQ:VMAR, that is real progress. It is not,...

Continue Reading

Top 5 Most Recently Viewed Articles

Strategic Planning for Long-Term and Short-Term Financial Success

Updated Category Investing Views 1297

Financial success rarely happens by accident. It requires deliberate planning, disciplined execution, and ongoing adjustments to align with changing circumstances. People often focus either on their short-term needs or their long-term goals, overlooking the importance of balancing them. A strong financial strategy incorporates immediate priorities while building a secure...

Continue Reading
Anticipating Caesars Entertainment's Upcoming Earnings Report

Updated Category News Views 259

A Look Ahead at Caesars Entertainment's Earnings Report Caesars Entertainment (NASDAQ: CZR) is on the verge of revealing its quarterly earnings report, drawing the interest of investors and market analysts alike. With anticipation building, here’s what the market expects before the announcement. Projected Earnings and Market Reactions Market analysts predict that...

Continue Reading
ResVita Bio's FDA Meeting Marks Progress for Netherton Syndrome

Updated Category News Views 215

ResVita Bio Advances Clinical Plans for Netherton Syndrome ResVita Bio, a biotechnology company focused on groundbreaking treatment options for skin diseases, recently shared exciting news about a pivotal meeting with the U.S. Food and Drug Administration (FDA). This engagement was crucial as it involved RVB-003, their leading investigational therapy targeted at...

Continue Reading
Solidion Technology Innovates to Advance Lithium-Sulfur Batteries

Updated Category News Views 235

Solidion Technology Makes Significant Advances in Battery Technology Solidion Technology, Inc. (NASDAQ: STI) has made remarkable progress in the field of battery technology, particularly with its lithium-sulfur (Li-S) batteries. Recently, Solidion announced a breakthrough in achieving a cell energy density of 380 Wh/kg, with future ambitions set at reaching 450 Wh/kg....

Continue Reading
Luray Peanut Co. Spices Up Snack Market with New Launch

Updated Category News Views 76

Spice Meets Peanut In An Unexpected Fusion Alright, let's shed some light on the latest concoction shaking up the snacking aisle. Luray Peanut Company has teamed up with none other than Texas Pete® to create a spicy new twist on boiled peanuts. Trust me, this is no typical snack partnership. Instead, it's the kind of daring venture that screams Southern soul with a...

Continue Reading